+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Global Cancer Monoclonal Antibodies Market - Growth, Trends, Forecasts 2017 - 2022

  • ID: 4388645
  • Report
  • Region: Global
  • 205 pages
  • Mordor Intelligence
1 of 3
The global cancer monoclonal antibodies market was valued at USD 27 billion for the year 2015 and is expected to grow at a CAGR of around 8-15% from 2015 to 2021.

The interaction between a person's genetic factor and other external agents (physical carcinogens, such as ultraviolet and ionizing radiation, chemical carcinogens, and biological carcinogens) can roughly be cited as the major cause of cancer. In 2012, the WHO reported 14 million new cancer cases and 8.2 million deaths due to cancer. The most common types of cancer that cause death are lung cancer, liver cancer, stomach cancer, colorectal cancer, breast cancer and esophageal cancer. There is a steady rise in the incidence of cancer annually. Drugs have not been able to provide a complete cure for any cancer. Moreover, all these drugs available as chemotherapeutic agents have adverse side-effects as they tend to affect the normal, healthy cells along with the cancerous cells. Hence, there is a huge amount of research and development going on all over the world to combat this deadly disease.

Global Cancer Monoclonal Antibodies Market-Market Dynamics

Monoclonal antibodies have the ability to identify cancer cells, bind to proteins on their surface and simulate an immune response. Due to their specificity, they are expected and have been proved to lessen the adverse effects of cancer to a much higher level. Most major pharmaceutical companies are investing in research on monoclonal antibodies. The drug research companies have also collaborated with many academics and institutions like National Institutes of Health, USA, National Cancer Institute, USA and many others for R&D in cancer drugs/ monoclonal antibodies. Due to the highly customizable nature of monoclonal antibodies, various organizations, research institutes, and companies are using it as a tool to target various cancers.


Large global patient pool

Severity of the disease

Unavailability of completely curing drugs

Side effects of the existing drugs

More specificity of monoclonal antibodies in targeting cancer cells


Stringent regulatory guidelines

Long duration of research and development

Long duration of clinical trials

High cost of research and development

The global cancer monoclonal antibody market has been segmented based on therapeutic application, types of monoclonal antibodies, and conjugated cancer therapies using monoclonal antibodies.

Based on the therapeutic application, the market is segmented into breast cancer, liver cancer, blood cancer, brain cancer, colorectal cancer, Hodgkins and non-Hodgkins lymphoma, leukemia, and others

Based on the types of monoclonal antibodies, the market is segmented into murine antibodies, chimeric and humanized antibodies, and fully humanized antibodies

Based on the conjugated cancer therapies using monoclonal antibodies, the market is segmented into immuno-liposome, radioimmunotherapy, ADEPT, and immunocytokines

Avastin, Rituxan, Bexxar, Kadcyla, Erbitux, Arzerra, Yervoy, Adcetris, and Herceptin are some of the well-marketed monoclonal antibodies. With only a few monoclonal antibodies in the market available exclusively for cancer therapies, there is always a good prospect for a new entrant. Conjugated therapies, using monoclonal antibodies, have been observed to give better results compared to stand-alone treatment. Currently, there is a trend towards more research in conjugated therapies. With the growing collaborations with institutes and companies, a very good market is expected in the near future. North America has the largest market for cancer monoclonal antibodies. India, China, and Australia are expected to have a large market in the near future.

Major Companies in the Sector Include:

This Report Offers:

Market definition along with identification of key drivers and restraints for the market.

Market analysis for the cancer monoclonal antibodies market, with region-specific assessments and competition analysis on a global and regional scale.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.

Identification and analysis of the macro and micro factors that affect the industry on both global and regional scale.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

An ideal source material for industry consultants, manufacturers and other interested and allied parties to gain a critical insight into the factors driving and restraining the market, in addition to opportunities offered.
Note: Product cover images may vary from those shown
2 of 3
1. Introduction
1.1 Study Deliverables
1.2 Market Definition
1.3 Sizing Units
1.4 Base Currency
1.5 Review and Forecast Period Years
1.6 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Analysis Methodology
2.3 Econometric Forecast Model
2.4 Research Assumptions
3. Executive Summary
4. Key Inferences
5. Market Overview and Industry Trends
5.1 Current Market Scenario
5.2 Cancer Monoclonal Antibody Applications
5.3 Technology Overview
5.4 New Developments
5.5 Industry Value Chain Analysis
5.6 Product Life Cycle Analysis
5.7 Product Benchmarking
5.8 Investment Analysis
5.9 Porter's Five Forces
5.9.1 Bargaining Power of Suppliers
5.9.2 Bargaining Power of Consumers
5.9.3 Threat to New Entrants
5.9.4 Threat to Substitute Products and Services
5.9.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis
6.1 Market Drivers
6.1.1 Large Global Patient Population
6.1.2 Severity of the Disease and Chronic Nature
6.1.3 Side Effects of Existing Drugs/ Therapy
6.1.4 Specificity of Monoclonal Antibodies
6.2 Market Restraints
6.2.1 Stringent Regulatory Guidelines
6.3 Key Challenges
6.3.1 High Research and Development Cost
6.3.2 Longer Duration of R&D and Clinical Trials
7. Market Segmentation
7.1 By Application
7.1.1 Breast Cancer
7.1.2 Non-Small Cell Lung Cancer
7.1.3 Neuroblastoma
7.1.4 Melanoma
7.1.5 Gastric Cancer
7.1.6 Leukemia
7.1.7 Hodgkin Lymphoma
7.1.8 Malignant Ascites
7.1.9 Colorectal Cancer
7.1.10 Non-Hodgkin Lymphoma
7.1.11 Brain Tumor
7.1.12 Lymphocytic Leukemia
7.1.13 Ovarian Cancer
7.1.14 Others
7.2 By types of Monoclonal Antibodies
7.2.1 Murine Antibodies
7.2.2 Chimeric and Humanized Antibodies
7.2.3 Fully Humanized Antibodies
7.3 By Conjugated Cancer Therapies Using Monoclonal Antibodies
7.3.1 Immunoliposomes
7.3.2 Radioimmunotherapy
7.3.3 Antibody Directed Enzyme Prodrug Therapy
7.3.4 Immunotoxins
7.3.5 Immunocytokines
7.3.6 Others
8. Market segmentation by Geography - Regional Share and Forecasts
8.1 North America
8.1.1 Introduction
8.1.2 United States
8.1.3 Canada
8.1.4 Rest of North America
8.2 Europe
8.2.1 Introduction
8.2.2 Germany
8.2.3 United Kingdom
8.2.4 France
8.2.5 Italy
8.2.6 Spain
8.2.7 Russia
8.2.8 Rest of Europe
8.3 Asia-Pacific (APAC)
8.3.1 Introduction
8.3.2 China
8.3.3 Japan
8.3.4 India
8.3.5 Australia
8.3.6 South Korea
8.3.7 Rest of Asia-Pacific
8.4 Middle East and Africa
8.4.1 Introduction
8.4.2 UAE
8.4.3 Saudi Arabia
8.4.4 Israel
8.4.5 Rest of Middle East & Africa
8.5 Latin America
8.5.1 Introduction
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Mexico
8.5.5 Rest of Latin America
9. Competitive Landscape
9.1 Merger and Acquisition Analysis
9.2 Patent Analysis
9.3 The Challenges
10. Key Vendor Analysis
10.1 Amgen Inc.
10.2 Bristol-Meyer Squibb
10.3 GlaxoSmithKline
10.4 Roche Holding
10.5 Spectrum Pharmaceuticals
10.6 Merck & Co. Inc.
10.7 Eli Lilly & Co.
10.8 ImmunoGen Inc.
10.9 Seattle Genetics
10.10 Janssen Biotech Inc.
10.11 Genmab
10.12 Novartis AG
11. Analyst Outlook for Investment Opportunities
12. Future Outlook of the Market
Note: Product cover images may vary from those shown
3 of 3